# Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma

> **NCT05512351** · PHASE2 · RECRUITING · sponsor: **Henan Provincial People's Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Oligodendroglioma

## Interventions

- **DRUG:** Tislelizumab plus Bevacizumab

## Key facts

- **NCT ID:** NCT05512351
- **Lead sponsor:** Henan Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-23
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2022-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05512351

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05512351, "Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Oligodendroglioma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05512351. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*